Patents by Inventor Liladhar Murlidhar Waykole

Liladhar Murlidhar Waykole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210393671
    Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.
    Type: Application
    Filed: August 31, 2021
    Publication date: December 23, 2021
    Inventors: Christoph Bucher, Dietmar Flubacher, Jeremiah Douglas Foutch, Malay Ghosh, Johannes Franz Kluge, Zaixing Li, Cale Ry McAlister, Liladhar Murlidhar Waykole, Jens Sören Worthmann, Tingying Zhu
  • Publication number: 20210340152
    Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 4, 2021
    Inventors: Ying Huang, Bo Liu, Liang Mao, Long Wang, Liladhar Murlidhar Waykole, Lijun Zhang
  • Patent number: 11135239
    Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: October 5, 2021
    Assignee: NOVARTIS AG
    Inventors: Christoph Bucher, Dietmar Flubacher, Jeremiah Douglas Foutch, Malay Ghosh, Johannes Franz Kluge, Zaixing Li, Cale Ry McAlister, Liladhar Murlidhar Waykole, Jens Sören Worthmann, Tingying Zhu
  • Publication number: 20210283171
    Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 16, 2021
    Inventors: Christoph Bucher, Dietmar Flubacher, Jeremiah Douglas Foutch, Malay Ghosh, Johannes Franz Kluge, Zaixing Li, Cale Ry McAlister, Liladhar Murlidhar Waykole, Jens Sören Worthmann, Tingying Zhu
  • Publication number: 20210253534
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2021
    Publication date: August 19, 2021
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Patent number: 11091489
    Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: August 17, 2021
    Assignee: Novartis AG
    Inventors: Ying Huang, Bo Liu, Liang Mao, Long Wang, Liladhar Murlidhar Waykole, Lijun Zhang
  • Patent number: 11021446
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 1, 2021
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Runyan Li, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang Wang, Liladhar Murlidhar Waykole, Yubo Zhang, Bo Zhou
  • Publication number: 20210155606
    Abstract: The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: February 8, 2021
    Publication date: May 27, 2021
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Patent number: 10947218
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: March 16, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • Patent number: 10934273
    Abstract: This application relates to various crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide hydrochloride salts as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including glioblastoma multiforme, breast cancer, pancreatic cancer and other solid tumors.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 2, 2021
    Assignee: Novartis AG
    Inventors: Arnaud Grandeury, Liladhar Murlidhar Waykole
  • Publication number: 20200299265
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 24, 2020
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Publication number: 20200247757
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Patent number: 10710980
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 14, 2020
    Assignee: Novartis AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • Publication number: 20200190057
    Abstract: This application relates to various crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide hydrochloride salts as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including glioblastoma multiforme, breast cancer, pancreatic cancer and other solid tumors.
    Type: Application
    Filed: October 13, 2017
    Publication date: June 18, 2020
    Inventors: Arnaud GRANDEURY, Liladhar Murlidhar WAYKOLE
  • Patent number: 10421755
    Abstract: The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 24, 2019
    Assignee: Novartis AG
    Inventors: Wolfgang Marterer, Mahavir Prashad, Edwin Bernard Villhauer, Liladhar Murlidhar Waykole, James Anthony Vivelo, Bertrand Sutter, Jean-Claude Bianchi, Raeann Wu, Denis Har, Piotr H. Karpinski, Massimo Pignone, Doris Stingelin, Eckart Buerger
  • Publication number: 20190211022
    Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 11, 2019
    Inventors: Ying HUANG, Bo LIU, Liang MAO, Long WANG, Liladhar Murlidhar WAYKOLE, Lijun ZHANG
  • Publication number: 20190161474
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: July 18, 2017
    Publication date: May 30, 2019
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Publication number: 20190062283
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: August 7, 2018
    Publication date: February 28, 2019
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Publication number: 20180009801
    Abstract: The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Inventors: Wolfgang Marterer, Mahavir Prashad, Edwin Bernard Villhauer, Liladhar Murlidhar Waykole, James Anthony Vivelo, Bertrand Sutter, Jean-Claude Bianchi, Raeann Wu, Denis Har, Piotr H. Karpinski, Massimo Pignone, Doris Stingelin, Eckart Buerger
  • Patent number: 9802931
    Abstract: The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 31, 2017
    Assignee: Novartis AG
    Inventors: Wolfgang Marterer, Mahavir Prashad, Edwin Bernard Villhauer, Liladhar Murlidhar Waykole, James Anthony Vivelo, Bertrand Sutter, Jean-Claude Bianchi, Raeann Wu, Denis Har, Piotr H. Karpinski, Massimo Pignone, Doris Stingelin, Eckart Buerger